Kavar Capital Partners Group LLC Acquires New Position in Illumina, Inc. $ILMN

Kavar Capital Partners Group LLC bought a new position in Illumina, Inc. (NASDAQ:ILMN) in the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund bought 4,056 shares of the life sciences company’s stock, valued at approximately $500,000.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in the business. Capital World Investors increased its holdings in shares of Illumina by 0.6% during the 4th quarter. Capital World Investors now owns 20,101,173 shares of the life sciences company’s stock worth $2,636,483,000 after buying an additional 124,323 shares during the last quarter. State Street Corp lifted its stake in shares of Illumina by 3.2% in the 4th quarter. State Street Corp now owns 6,190,114 shares of the life sciences company’s stock valued at $811,895,000 after purchasing an additional 190,324 shares in the last quarter. AQR Capital Management LLC increased its position in Illumina by 30.3% during the 4th quarter. AQR Capital Management LLC now owns 4,426,126 shares of the life sciences company’s stock worth $580,531,000 after purchasing an additional 1,028,099 shares in the last quarter. Geode Capital Management LLC raised its holdings in Illumina by 4.8% in the fourth quarter. Geode Capital Management LLC now owns 2,869,047 shares of the life sciences company’s stock valued at $375,260,000 after buying an additional 130,139 shares during the period. Finally, Invesco Ltd. grew its stake in Illumina by 97.0% during the fourth quarter. Invesco Ltd. now owns 2,747,986 shares of the life sciences company’s stock worth $360,426,000 after buying an additional 1,352,731 shares during the period. Hedge funds and other institutional investors own 89.42% of the company’s stock.

Illumina Price Performance

Shares of NASDAQ:ILMN opened at $161.93 on Friday. The company has a market cap of $24.50 billion, a PE ratio of 29.44, a P/E/G ratio of 3.03 and a beta of 1.50. Illumina, Inc. has a fifty-two week low of $88.00 and a fifty-two week high of $177.22. The firm has a 50-day simple moving average of $145.20 and a 200 day simple moving average of $136.16. The company has a quick ratio of 1.36, a current ratio of 1.75 and a debt-to-equity ratio of 0.56.

Illumina (NASDAQ:ILMN) last posted its earnings results on Thursday, April 30th. The life sciences company reported $1.15 EPS for the quarter, beating the consensus estimate of $1.05 by $0.10. The company had revenue of $1.09 billion during the quarter, compared to analyst estimates of $1.07 billion. Illumina had a return on equity of 31.01% and a net margin of 19.42%.The business’s revenue was up 4.8% compared to the same quarter last year. During the same period in the prior year, the company earned $0.97 earnings per share. Illumina has set its FY 2026 guidance at 5.150-5.300 EPS. On average, sell-side analysts anticipate that Illumina, Inc. will post 5.21 EPS for the current year.

Insider Activity at Illumina

In related news, Director Keith A. Meister sold 235,000 shares of the business’s stock in a transaction that occurred on Monday, June 1st. The stock was sold at an average price of $163.63, for a total transaction of $38,453,050.00. Following the sale, the director owned 2,830,452 shares of the company’s stock, valued at $463,146,860.76. The trade was a 7.67% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, CAO Scott D. Ericksen sold 1,500 shares of the stock in a transaction on Thursday, May 28th. The shares were sold at an average price of $150.10, for a total value of $225,150.00. Following the transaction, the chief accounting officer directly owned 14,946 shares of the company’s stock, valued at approximately $2,243,394.60. The trade was a 9.12% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 1,003,154 shares of company stock worth $155,600,208 in the last ninety days. 2.90% of the stock is currently owned by corporate insiders.

Analyst Upgrades and Downgrades

ILMN has been the topic of a number of analyst reports. Royal Bank Of Canada initiated coverage on shares of Illumina in a research note on Thursday, May 14th. They set an “outperform” rating and a $170.00 price objective on the stock. Evercore reaffirmed an “outperform” rating on shares of Illumina in a research note on Friday, May 1st. Citigroup raised their target price on Illumina from $80.00 to $95.00 and gave the company a “sell” rating in a research note on Monday, May 4th. Guggenheim boosted their price target on Illumina from $170.00 to $180.00 and gave the stock a “buy” rating in a research note on Monday, June 1st. Finally, Wall Street Zen downgraded Illumina from a “strong-buy” rating to a “buy” rating in a report on Saturday, May 9th. Eight investment analysts have rated the stock with a Buy rating, eight have given a Hold rating and two have assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Hold” and an average price target of $142.12.

Illumina Profile

Illumina, Inc (NASDAQ: ILMN) is a global life sciences company that develops, manufactures and markets integrated systems for the analysis of genetic variation and function. Headquartered in San Diego, California and founded in 1998, Illumina offers a range of sequencing and array-based technologies used by academic researchers, clinical laboratories, pharmaceutical and biotechnology companies, consumer genomics firms and agricultural researchers to enable discovery, translational research and clinical applications.

The company’s product portfolio includes next-generation sequencing (NGS) platforms and associated consumables, microarrays for genotyping and methylation analysis, library preparation kits and targeted assays.